Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jun 25;10(13):2803.
doi: 10.3390/jcm10132803.

Molecular Subtypes and Precision Oncology in Intrahepatic Cholangiocarcinoma

Carolin Czauderna  1 , Martha M Kirstein  1 , Hauke C Tews  1   2 , Arndt Vogel  3 , Jens U Marquardt  1
Affiliations
Review

Molecular Subtypes and Precision Oncology in Intrahepatic Cholangiocarcinoma

Carolin Czauderna et al. J Clin Med. .

Abstract

Cholangiocarcinomas (CCAs) are the second-most common primary liver cancers. CCAs represent a group of highly heterogeneous tumors classified based on anatomical localization into intra- (iCCA) and extrahepatic CCA (eCCA). In contrast to eCCA, the incidence of iCCA is increasing worldwide. Curative treatment strategies for all CCAs involve oncological resection followed by adjuvant chemotherapy in early stages, whereas chemotherapy is administered at advanced stages of disease. Due to late diagnosis, high recurrence rates, and limited treatment options, the prognosis of patients remains poor. Comprehensive molecular characterization has further revealed considerable heterogeneity and distinct prognostic and therapeutic traits for iCCA and eCCA, indicating that specific treatment modalities are required for different subclasses. Several druggable alterations and oncogenic drivers such as fibroblast growth factor receptor 2 gene fusions and hotspot mutations in isocitrate dehydrogenase 1 and 2 mutations have been identified. Specific inhibitors have demonstrated striking antitumor activity in affected subgroups of patients in phase II and III clinical trials. Thus, improved understanding of the molecular complexity has paved the way for precision oncological approaches. Here, we outline current advances in targeted treatments and immunotherapeutic approaches. In addition, we delineate future perspectives for different molecular subclasses that will improve the clinical care of iCCA patients.

Keywords: FGFR; IDH1; cholangiocarcinoma; immunotherapy; targeted therapy.

PubMed Disclaimer

Conflict of interest statement

J.U.M. received honoraria from Roche, Bayer, Ipsen, Merz, AstraZeneca, Johnson & Johnson, MSD, Leap-Tx, and Eisai. A.V. received honoraria as a speaker, consultant, and advisor from Roche, Bayer, Sanofi, BMS, Lilly, Novartis, EISAI, AstraZeneca, Merck, Incyte, Ipsen, PierreFabre, MSD, and Janssen. C.C. reports receiving consulting fees from MSD and lecture fees from EISAI.

Figures

Figure 1
Figure 1
Molecular alterations of cholangiocarcinoma (CCA) subtypes. AT-Rich Interaction Domain 1A (AIRD1A); BRCA1 Associated Protein 1 (BAP-1); proto-oncogene B-Raf (BRAF); Ductus hepaticus communis (DHC); human epidermal growth factor receptor 2 (Her2); E74 Like ETS Transcription Factor 3 (ELF3); Ephrin type-A receptor 2 (EPHA2); Erb-B2 Receptor Tyrosine Kinase 3 (ERBB3); Fibroblast Growth Factor Receptor gene 2 (FGFR 2), Isocitrate dehydrogenase 1 and 2 (IDH1/2); Kirsten rat sarcoma (KRAS); Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha (PIK3CA); Protein Kinase CAMP-Activated Catalytic Subunit Alpha/-Beta (PRKACA/-B); SMAD family member 4 (SMAD4); Tumor Protein P53 (TP53).
Figure 2
Figure 2
Conventional and precision oncological treatment approaches in advanced intrahepatic cholangiocarcinomas (iCCAs). proto-oncogene B-Raf (BRAF); human epidermal growth factor receptor 2 (Her2); Fibroblast Growth Factor Receptor gene 2 (FGFR 2), Isocitrate dehydrogenase 1 and 2 (IDH1/2); Neurotrophic tyrosine receptor kinase (NTRK); microsatellite instability (MSI).
See this image and copyright information in PMC

References

    1. Neumann U.P., Schmeding M. Role of surgery in cholangiocarcinoma: From resection to transplantation. Best Pract. Res. Clin. Gastroenterol. 2015;29:295–308. doi: 10.1016/j.bpg.2015.02.007. - DOI - PubMed
    1. van der Gaag N.A., Kloek J.J., de Bakker J.K., Musters B., Geskus R.B., Busch O.R.C., Bosma A., Gouma D.J., van Gulik T.M. Survival analysis and prognostic nomogram for patients undergoing resection of extrahepatic cholangiocarcinoma. Ann. Oncol. 2012;23:2642–2649. doi: 10.1093/annonc/mds077. - DOI - PubMed
    1. Spolverato G., Yakoob M.Y., Kim Y., Alexandrescu S., Marques H.P., Lamelas J., Aldrighetti L., Gamblin T.C., Maithel S.K., Pulitano C., et al. The Impact of Surgical Margin Status on Long-Term Outcome After Resection for Intrahepatic Cholangiocarcinoma. Ann. Surg. Oncol. 2015;22:4020–4028. doi: 10.1245/s10434-015-4472-9. - DOI - PubMed
    1. Valle J., Wasan H., Palmer D.H., Cunningham D., Anthoney A., Maraveyas A., Madhusudan S., Iveson T., Hughes S., Pereira S.P., et al. Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer. N. Engl. J. Med. 2010;362:1273–1281. doi: 10.1056/NEJMoa0908721. - DOI - PubMed
    1. Ebata T., Hirano S., Konishi M., Uesaka K., Tsuchiya Y., Ohtsuka M., Kaneoka Y., Yamamoto M., Ambo Y., Shimizu Y., et al. Randomized clinical trial of adjuvant gemcitabine chemotherapy versus observation in resected bile duct cancer. BJS. 2018;105:192–202. doi: 10.1002/bjs.10776. - DOI - PubMed

LinkOut - more resources